Back to search results

B7-H3 CAR T-Cell Immunotherapy for Pediatric Brain Tumors

This study is testing a new type of immunotherapy called SCRI-CARB7H3(s) for children and young adults (ages 1 to 26) with certain brain tumors, including Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse Midline Glioma (DMG), and other recurrent or refractory central nervous system (CNS) tumors. SCRI-CARB7H3(s) uses your own immune cells (T cells) that are specially modified to recognize and fight cancer cells. These modified T cells are delivered directly into the brain through a catheter. The main goals of this study are to see if this treatment is safe and if it's possible to produce and give these CAR T cells.

Study design
This is an interventional study with a planned enrollment of 90 participants. It is a Phase 1 study, meaning it focuses on safety and feasibility.
What's involved
You would need to be able to have your T cells collected (apheresis) and have a CNS catheter, like an Ommaya or Rickham catheter, in place.
Compensation
Not stated in the trial record.
Follow-up
The study will assess safety for up to 7 months and feasibility for 28 days after the CAR T cell infusions.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04185038

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Recruiting
PHASE1Ages 1–26InterventionalTreatment
Seattle Children's Hospital
~90 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Establish the safety, defined by the adverse events, of B7H3-specific CAR T cell infusions delivered by a central nervous system (CNS) catheter into the tumor resection cavity or ventricular system
Measured over up to 7 months
+1 more outcome measured

Conditions

Central Nervous System Tumor
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma
Ependymoma
Medulloblastoma, Childhood
Germ Cell Tumor
Atypical Teratoid/Rhabdoid Tumor
Primitive Neuroectodermal Tumor
Choroid Plexus Carcinoma
Pineoblastoma, Childhood
Glioma

Explore related trials

Atypical Teratoid/Rhabdoid TumorCentral Nervous System NeoplasmChoroid Plexus CarcinomaDiffuse Intrinsic Pontine GliomaDiffuse Midline GliomaEpendymomaGerm Cell TumorGliomaMedulloblastomaPineoblastomaPrimitive Neuroectodermal TumorCD276 wt AlleleSoluble Epidermal Growth Factor Receptor

Where it's being run

1 sites across 1 states
Washington1

Study leadership

  • Rebecca Ronsley, MD · STUDY_CHAIR · Seattle Children's Hospital

Who to contact

Rebecca Ronsley, MD
[email protected]
206-987-2106
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Establish the safety, defined by the adverse events, of B7H3-specific CAR T cell infusions delivered by a central nervous system (CNS) catheter into the tumor resection cavity or ventricular systemup to 7 months

    The type, frequency, severity, and duration of adverse events as a result of B7H3-specific CAR T cell infusion will be summarized

  • Establish the feasibility, defined by the ability to produce and administer CAR T cell product, of B7H3-specific CAR T cell product infusions delivered by a central nervous system (CNS) catheter into the tumor resection cavity or ventricular system28 days

    The proportion of products successfully manufactured and infused will be measured